Atom | Early Stage Testing of Pharmacologic or Neuromodulatory Device-based Interventions for the Treatment of Mental Disorders (R61/R33 Clinical Trial Required)

Funder: National Institutes of Health

Funding Amounts: No budget cap; up to 5 years total (2 years R61, 3 years R33); $27M total program funding (FY26, across NOFOs)

Summary: Supports early-stage clinical trials of novel pharmacologic or neuromodulatory device-based interventions for mental disorders, requiring both clinical effect and mechanistic evaluation.

Key Information: R61/R33 biphasic structure; clinical trial required; both phases must be proposed; foreign and domestic applicants eligible.

Early Stage Testing of Pharmacologic or Neuromodulatory Device-based Interventions for the Treatment of Mental Disorders (R61/R33 Clinical Trial Required)

Sign in to see full grant listing